Financials in USD. Standardized financial statements.
A compact view of how Can-Fite BioPharma Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $408,212 | $674,000 | $743,000 | $810,000 | $853,000 | $763,000 | $2.03M | $3.82M | $844,746 | $169,500 |
| Revenue Growth? | -39.4% | -9.3% | -8.3% | -5.0% | +11.8% | -62.5% | -46.8% | +352.2% | +398.4% | 0.0% |
| Cost of Revenue? | $24,190 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $384,022 | $674,000 | $743,000 | $810,000 | $853,000 | $763,000 | $2.03M | $3.82M | $844,746 | $169,500 |
| Gross Margin? | +94.1% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $10.41M | $8.80M | $8.94M | $10.91M | $13.70M | $14.90M | $14.04M | $9.23M | $8.22M | $8.80M |
| Operating Income? | -$10.03M | -$8.13M | -$8.20M | -$10.10M | -$12.84M | -$14.14M | -$12.01M | -$5.41M | -$7.38M | -$8.63M |
| EBITDA? | -$10.00M | -$8.12M | -$8.18M | -$10.08M | -$12.83M | -$14.13M | -$11.99M | -$6.13M | -$7.17M | -$8.68M |
| Income Before Tax | -$9.91M | -$7.88M | -$7.63M | -$10.17M | -$12.62M | -$14.44M | -$12.63M | -$6.57M | -$4.95M | -$6.99M |
| Income Tax Expense | $0 | $0 | $0 | $360,000 | -$20,000 | $0 | $427,000 | $4,000 | $29,922 | $29,116 |
| Net Income? | -$9.91M | -$7.88M | -$7.63M | -$10.17M | -$12.60M | -$14.44M | -$12.63M | -$6.57M | -$4.97M | -$6.90M |
| EPS? | $-12.03 | $-1.08 | $-1.80 | $-3.75 | $-9.00 | $-12.69 | $-45.00 | $-51.00 | $-57.00 | $-90.00 |
| Diluted EPS? | $-12.03 | $-1.08 | $-1.80 | $-3.75 | $-8.25 | $-12.69 | $-45.00 | $-51.00 | $-57.00 | $-90.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality